CMO

ProMetic Life Sciences Inc. (TSX:PLI)(OTCQX:PFSCF), ("ProMetic" or the
"Corporation") announced today the appointment of Dr. John Moran as its new
Chief Medical Officer ("CMO"), effective as of March 1st, 2014. 


Before joining ProMetic as its new CMO, Dr. Moran MD, FRACP, FACP, FACPE, served
as Vice President, Clinical Affairs - Home Modalities at DaVita HealthCare
Partners, Inc. where he was responsible for the quality of care and related
business issues for over 20,000 home dialysis patients in over 900 care centers.
Dr. Moran is also a Consulting Professor in the Division of Nephrology at
Stanford University School of Medicine. Previously, Dr. Moran served for 7 years
as Senior Vice President, Clinical Affairs for Satellite Healthcare, 4 years as
Senior Vice President and Chief Medical Officer for Vasca Inc. and more than 3
years as Vice President for Clinical Development and Marketing for the Renal
Division of Baxter Healthcare Corporation.


"I am thrilled to be joining ProMetic as its new Chief Medical Officer at such a
critical time in its clinical development phase. As a member of ProMetic's Board
of Directors for the past 2 years, I have closely followed the expansion of
ProMetic's compounds into a compelling therapeutic franchise. As a physician, it
will be my privilege to see ProMetic's small molecule drug candidates and plasma
derived therapeutics finally address many severe unmet medical conditions and so
significantly improve the quality of life and outcomes for potentially thousands
of patients" said Dr. Moran. "As evidenced by the first-in-class efficacy
demonstrated in some of the most stringent preclinical fibrotic models and the
recent successful operational launch of the plasma purification facility,
ProMetic is now well positioned to become a leading provider of innovative
medical therapies", added Dr. Moran. 


"Our recent progress and further anticipated advancement of our lead drug
candidates have made the creation of the Chief Medical Officer position a
corporate priority. We believe that Dr. Moran is the perfect candidate to help
us successfully bring forward our compounds through the regulatory pathway given
his deep knowledge of both ProMetic and industry at large. His wealth of
expertise in senior executive positions related to clinical affairs, clinical
development and marketing in the field of nephrology and end-stage renal
diseases will play a key role in the development of our valuable clinical
assets", commented Mr. Pierre Laurin, President and Chief Executive Officer of
ProMetic. 


About ProMetic Life Sciences Inc. 

ProMetic Life Sciences Inc. (www.prometic.com) is a long established
biopharmaceutical company with globally recognized expertise in bioseparation,
plasma-derived therapeutics and small-molecule drug development. ProMetic offers
its state of the art technologies for large-scale purification of biologics,
drug development, proteomics and the elimination of pathogens to a growing base
of industry leaders and uses its own affinity technology that provides for
highly efficient extraction and purification of therapeutic proteins from human
plasma in order to develop best-in-class therapeutics and orphan drugs. ProMetic
is also active in developing its own novel small-molecule therapeutic products
targeting unmet medical needs in the field of fibrosis, cancer and autoimmune
diseases/inflammation. Headquartered in Laval (Canada), ProMetic has R&D
facilities in the UK, the U.S. and Canada, manufacturing facilities in the UK
and business development activities in the U.S., Europe and Asia. 


Forward Looking Statements 

This press release contains forward-looking statements about ProMetic's
objectives, strategies and businesses that involve risks and uncertainties.
These statements are "forward-looking" because they are based on our current
expectations about the markets we operate in and on various estimates and
assumptions. Actual events or results may differ materially from those
anticipated in these forward-looking statements if known or unknown risks affect
our business, or if our estimates or assumptions turn out to be inaccurate. Such
risks and assumptions include, but are not limited to, ProMetic's ability to
develop, manufacture, and successfully commercialize value-added pharmaceutical
products, the availability of funds and resources to pursue R&D projects, the
successful and timely completion of clinical studies, the ability of ProMetic to
take advantage of business opportunities in the pharmaceutical industry,
uncertainties related to the regulatory process and general changes in economic
conditions. You will find a more detailed assessment of the risks that could
cause actual events or results to materially differ from our current
expectations on page 26 of ProMetic's Annual Information Form for the year ended
December 31, 2012, under the heading "Risk and Uncertainties related to
ProMetic's business". As a result, we cannot guarantee that any forward-looking
statement will materialize. We assume no obligation to update any
forward-looking statement even if new information becomes available, as a result
of future events or for any other reason, unless required by applicable
securities laws and regulations. All amounts are in Canadian dollars unless
indicated otherwise.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Pierre Laurin
President and CEO
ProMetic Life Sciences Inc.
p.laurin@prometic.com
+1.450.781.0115


Frederic Dumais
Director, Communications and
Investor Relations
ProMetic Life Sciences Inc.
f.dumais@prometic.com
+1.450.781.0115

Grafico Azioni Cliffmont Resources Ltd. (TSXV:CMO)
Storico
Da Mag 2024 a Giu 2024

Grafico Azioni Cliffmont Resources Ltd. (TSXV:CMO)
Storico
Da Giu 2023 a Giu 2024